Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Omoto

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Antiviral Research|October 15, 2018
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunitTakeshi Noshi, Mitsutaka Kitano, Keiichi Taniguchi, et al.
Plos Pathogens|May 6, 2021
Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret modelLeo Y Lee, Jie Zhou, Paulina Koszalka, et al.
NPJ Vaccines|March 30, 2026
IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific mannerYuya Yoshioka, Anri Nishinaka-Yoshioka, Kouji Kobiyama, et al.
Vaccine|June 12, 2022
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeysMasayuki Hashimoto, Noriyo Nagata, Tomoyuki Homma, et al.
Scientific Reports|December 2, 2022
Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in miceTomoyuki Homma, Noriyo Nagata, Masayuki Hashimoto, et al.
Frontiers in Immunology|March 20, 2025
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost studyMasaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Antiviral Research|October 15, 2018
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunitTakeshi Noshi, Mitsutaka Kitano, Keiichi Taniguchi, et al.
Plos Pathogens|May 6, 2021
Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret modelLeo Y Lee, Jie Zhou, Paulina Koszalka, et al.
NPJ Vaccines|March 30, 2026
IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific mannerYuya Yoshioka, Anri Nishinaka-Yoshioka, Kouji Kobiyama, et al.
Vaccine|June 12, 2022
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeysMasayuki Hashimoto, Noriyo Nagata, Tomoyuki Homma, et al.
Scientific Reports|December 2, 2022
Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in miceTomoyuki Homma, Noriyo Nagata, Masayuki Hashimoto, et al.
Frontiers in Immunology|March 20, 2025
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost studyMasaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, et al.
Pageof 4